The pathways to lymphoid neoplasia have been explored in a number of transgenic models. Because B lymphoid malignancies often involve translocation of an oncogene (e.g. myc, bcl-2, cyclin D1) to an immunoglobulin locus, resulting in its deregulated expression, the consequences of oncogene overexpression in lymphocytes can be evaluated with transgenes driven by an immunoglobulin regulatory element, such as an enhancer from the IgH locus. Mice bearing such transgenes have provided insight into the preneoplastic state, including alterations in the control of cellular proliferation, dierentiation or apoptosis. They have also allowed studies on oncogene cooperation in vivo and the modulating eect of genetic background. Brie¯y reviewed here are the models studied in the authors' laboratories. Mice bearing myc and bcl-2 transgenes have received most attention but others studied include abl, ras, cyclin D1 and bmi-1 oncogenes. Also discussed is a new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias. The vector bears elements from the promoter region of the vav gene, which is expressed almost exclusively in hematopoietic cells. It has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. This novel vector should aid studies on many aspects of hematopoiesis, including the modeling of leukemogenesis.
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Keywords: lymphoma; leukemia; oncogene; transgenic vectors; hematopoiesis As reviewed previously Adams and Cory, 1991a,b; Adams et al., 1991) , transgenic models have provided an invaluable resource for molecular oncology by revealing the consequences of putative tumorigenic mutations in the most relevant context, namely the living animal. With an appropriate choice of regulatory elements, the impact of an oncogene can be studied in the most pertinent normal cell type rather than in cell lines that have unknown and variable mutational histories. As well as tumorigenic potential, one can evaluate how the introduced oncogene aects cell cycling, dierentiation and apoptosis. These models provide new avenues to study the pre-neoplastic state, including long-term pathological eects. Moreover, the enhanced susceptibility of the relevant cell population in these animals to chemical and biological agents makes them an important resource for uncovering the various pathways to full¯edged malignancy. In particular, cross breeding of two cancer-prone strains can test cooperativity between dierent known oncogenic mutations. Moreover, insertional mutagenesis with retroviruses can be used to identify oncogenic partners, including previously unknown genes. Finally, the availability of numerous inbred strains of mice, which can vary markedly in susceptibility to dierent types of malignancies, raises the prospect of uncovering modi®er loci that in¯uence the impact of particular oncogenes or tumor suppressor genes. The strengths of this experimental approach ensure that mice engineered to express particular oncogenes or to lack speci®c tumor suppressors will continue to illuminate the complex genetic scenario that underlies malignancy.
The ®rst aim of this review will be to sketch some of the ®ndings from transgenic models for lymphomagenesis, with illustrations drawn mainly from studies in our own laboratories. Our studies were triggered by an interest in the translocations found in B-lymphoid tumors, which almost invariably couple a putative oncogene to an immunoglobulin locus, thereby subjecting the translocated gene to regulatory elements of that locus, such as the enhancer (Em) near the Cm gene (Cory, 1986) . Consequently, our ®rst transgenic study mimicked the prototypic myc-Igh translocation by linking Em to the c-myc gene (Adams et al., 1985) , and that regulatory element has also featured in much of our subsequent work. The models we have studied are summarized in Table 1 . More extensive discussion of these and other models of lymphomagenesis, including related work by other laboratories, can be found in earlier reviews Adams and Cory, 1991a,b; Adams et al., 1991; Berns et al., 1994; Jonkers and Berns, 1996; Chao and Korsmeyer, 1998) . Because the role played in tumorigenesis by altered apoptosis has increasingly occupied our attention, several of our other reviews concentrate on how its prototypic regulator Bcl-2 (Vaux et al., 1988) aects normal lymphoid homeostasis and contributes to lymphomagenesis (Cory et al., 1994a,b; Cory, 1995; Strasser, 1995b Strasser, , 1999 Strasser et al., 1996b Strasser et al., , 1997a Cory et al., 1999) .
Eective transgenic vectors for the lymphoid compartment have been essential for the development of lymphomagenic models. The transgenic analysis of non-lymphoid leukemias has been more problematic (Westervelt and Ley, 1999) , in part because the available vectors for myeloid cells are active in only a single lineage or at a speci®c stage of dierentiation (e.g. Lagasse and Weissman, 1994) . On the other hand, a vector expressed widely in the hematopoietic system but also in other tissues, such as the class I MHC promoter (Domen et al., 1998) , might lead to confusing indirect eects. A vector that targeted expression speci®cally to the entire hematopoietic system, particularly its stem cell compartment, would significantly facilitate studies on the basis of leukemogenesis, as well as other aspects of hematopoiesis. The second aim of this review will be to sketch our eorts over recent years to develop such a vector, based on the vav gene, which is expressed almost exclusively in hematopoietic cells (Katzav et al., 1989; Bustelo et al., 1993) . Delineating the regulatory elements needed for its expression in vivo (Ogilvy et al., 1998) has recently allowed us to develop a novel vector that appears to be highly eective for this compartment (Ogilvy et al., 1999) .
Transgenic models of lymphomagenesis

Vectors for the lymphoid compartment
As indicated above, the chief regulatory element present in the vectors we have used is Em. Our studies have shown that this enhancer drives transgene expression throughout the B-lymphoid lineage from a very early stage, sometimes also in the T-cell lineage, and occasionally in certain myeloid cells (Strasser et al., 1990a) . Because our Em vectors are designed primarily for use with a cDNA insert, they include a promoter, an intron and a poly-A addition signal, all necessary for ecient expression, and the SV40 sequences present facilitate the identi®cation of transgenic pups by PCR or DNA dot-blot hybridization. The Em-based vectors typically give an acceptable level of expression in at least one-third of primary transgenic animals, and the level is consistently maintained in all transgenic progeny of the selected founders. One of our more successful vectors, denoted EmSV (Rosenbaum et al., 1989) , which includes the promoter from the early region of SV40, usually drives expression almost exclusively in the B-cell lineage but in a minority of primary transgenic animals it also functions in T cells. Our preferred lymphoid vector at present (denoted EmSR) (Bodrug et al., 1994) uses a modi®ed SV40 promoter (SRa) known to give higher expression in lymphoid cell lines (Takebe et al., 1988) . It is often expressed in both T and B cells, as are the Em-based vectors developed by Berns and co-workers (Alkema et al., 1997) . For expression con®ned to the T-cell lineage, a vector based on the lck proximal promoter (Chan et al., 1990; Newton et al., 1998) or the CD2 locus control region (Festenstein et al., 1996) is preferable.
Myc
Expression of the c-myc gene is consistently associated with cellular proliferation, and the encoded basic region ± helix ± loop ± helix ± leucine zipper transcription factor is now thought to be essential for driving expression of several genes, such as cdc25A, needed to maintain cell cycle progression (Galaktionov et al., 1996; Grandori and Eisenman, 1997) . The discovery by several groups, including ours, that the translocations present in Burkitt's lymphomas and mouse plasmacytomas juxtaposed the myc gene and an immunoglobulin locus (Cory, 1986) prompted us to exploit transgenic mice to test the consequences of the translocation. Within the ®rst year of life nearly every mouse carrying an Em-myc transgene succumbed to an aggressive pre-B-or B-cell lymphoma accompanied by lymphoblastic leukemia (Adams et al., 1985; Harris et al., 1988b) .
Despite this high tumorigenic impact, young Em-myc mice lacked transplantable tumor cells (Langdon et al., 1986) , and the randomly arising tumors were clonal (Harris et al., 1988b) . Indeed, calculations suggested that a tumorigenic clone arose only after some 10 10 cell divisions (Harris et al., 1988b) , indicative of the need for at least one and probably two mutations in addition to constitutive myc expression. Mutation of N-ras or K-ras was implicated in a minority of the tumors (Alexander et al., 1989a,b) , and the p53 tumor suppressor gene was altered or lost in some (Cory et al., 1999) . Although the dominant pathway to the spontaneous tumors remains uncertain, several oncogenic changes have been shown to collaborate with myc.
Young tumor-free Em-myc mice displayed a 4 ± 5-fold elevation in pre-B cells but a slight drop in mature B cells (Langdon et al., 1986) . Notably, nearly all of these cells appeared to be in cycle. These ®ndings suggested that myc may help to govern cellular dierentiation, with high Myc levels promoting selfregenerative divisions of the precursor cell and lower An alteration in lymphoid development was only observed in a strain with particularly hugh bmi-1 expression (Alkema et al., 1997) levels allowing continued maturation (Langdon et al., 1986) . Thus, constitutive myc expression may prevent exit from the cell cycle and force entry of normally quiescent cells into cycle.
Although myc expression is induced by growth factors or stimulation of antigen receptors, its overexpression does not in itself allow cellular autonomy, because culture of Em-myc lymphocytes revealed no loss of growth factor requirements (Vaux et al., 1987; Langdon et al., 1988) . Indeed, although the cultured pre-B cells remained in cycle, they grew to densities only twice that of their normal counterparts (Langdon et al., 1988) . The plateau in their growth both in vitro and in vivo re¯ects a balance between increased proliferation and increased cell death. In the animal, the aected population presumably expands until growth factors become limiting. In keeping with that notion, Myc-driven cells deprived of cytokines survived in culture much less well than non-transgenic controls (Langdon et al., 1988; Strasser et al., 1996a) . Cleveland and Evan and their colleagues have shown that under such adverse growth conditions Myc promotes programmed cell death (apoptosis) (Askew et al., 1991; Evan et al., 1992) .
Although myc is regarded as an immortalizing oncogene, emergence of autonomous myc-driven cell lines required many weeks of culture (Langdon et al., 1988; Schmidt et al., 1988) , and cells from young Emmyc mice were not transplantable, suggesting that additional mutations were required to allow inde®nite clonal expansion (Langdon et al., 1986; Harris et al., 1988b) . Thus, Myc is not sucient for immortalization, although it does contribute. An important recent clue to its immortalizing role may be that Myc appears to induce expression of telomerase, which can maintain telomere length and thereby extend the normal clonal lifespan thought to be set by telomere erosion (Wang et al., 1998; Greenberg et al., 1999) .
Although N-Myc is very similar in structure to cMyc, it has been implicated primarily in nonhematopoietic tumors such as neuroblastoma and small cell lung carcinomas and its normal expression pattern is much more restricted than that of c-Myc. Hence it was of interest to learn whether N-myc, if aberrantly expressed in lymphocytes, would function similarly to c-myc. Indeed, Em-N-myc mice also displayed a marked increase in cycling pre-B cells and developed pre-B and B lymphomas (Dildrop et al., 1989; Rosenbaum et al., 1989) . Interestingly, apparently due to cross-regulation between Myc family members, these tumors lacked expression of c-myc. This result suggested that N-Myc can completely supplant c-Myc in cellular proliferation as well as lymphomagenesis (Rosenbaum et al., 1989) . Gene replacement in the germline of mice has recently extended that conclusion to the whole animal (Fred Alt, personal communication) .
The function of Myc as a transcription factor requires its association with the related helix ± loop ± helix ± zipper protein Max, which is constitutively expressed, but Max can also dimerize with proteins such as Mad, whose action may oppose that of Myc (Hurlin et al., 1994) . Therefore, it was of interest to determine whether over-expression of Max would augment or depress Myc biological functions. Substantial over-expression of Max elicited by an Em-max transgene did not provoke lymphomas nor disturb lymphopoiesis, except for a modest drop in B lymphoid cells (Lindeman et al., 1995) . In animals also bearing an Em-myc transgene, however, both the expansion of the pre-B cell compartment and the rate of lymphoma onset were reduced compared to mice carrying Em-myc alone. This result is consistent with cell culture studies showing that excess Max reduces Myc transcriptional activity, perhaps because MaxMax or Max-Mad dimers compete for the same sites (Hurlin et al., 1994) .
From the current perspective, what can be said about the tumorigenic action of Myc? Its impact is both quantitative and qualitative. In the Em-myc mice, because all the cells seem to be continuously cycling and the aected compartment is expanded, the vulnerable cell population undergoes an order of magnitude more cell divisions than normal (Harris et al., 1988b) . Since mutations are generally thought to occur during replication of the genome, the odds of somatic mutation should increase correspondingly. It also remains possible that Myc overexpression increases the intrinsic likelihood of further mutation (Felsher and Bishop, 1999) . The ability of Myc to induce apoptosis when growth factors become limiting may well also be relevant, because it would impose strong selection for any rare clone bearing a mutation that, directly or indirectly, reduces apoptosis. Finally, the potential of Myc to induce telomerase (see above) must facilitate the eventual inexorable growth of the malignant clone.
Abl
Amino-terminally altered forms of the c-abl tyrosine kinase have been associated with several forms of hematopoietic malignancy. The 9;22 translocation characteristic of chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia replaces the 5' portion of the abl gene with that of the bcr gene, whereas a somewhat analogous gag-abl fusion gene (v-abl) allows Abelson murine leukemia virus to generate pre-B and T lymphomas and to accelerate development of plasmacytomas in BALB/c mice also treated with pristane. How these oncogenic forms contribute to the neoplastic state remains poorly understood, although they have been postulated to inhibit apoptosis and/or to activate signaling pathways normally induced by growth factors (Raitano et al., 1997) .
An Em-v-abl transgene proved to be highly tumorigenic. Surprisingly, however, three lines of these mice developed only plasmacytoma, whereas a fourth instead developed exclusively pre-B and T lymphomas (Rosenbaum et al., 1990) . We surmise that transgene expression commences earlier in B-cell ontogeny for the lymphomagenic line. The generation of tumors of the pre-B cell and the plasma cell but none from the mature B cell suggests that v-ablinduced oncogenesis is highly speci®c for particular developmental stages. Interestingly, 80% of the plasmacytomas displayed evidence of myc translocations, often to the Igh Ca locus, suggesting that a myc translocation may be the rate-limiting step for plasmacytoma development in Em-v-abl mice. In con®rmation of that notion, Em-myc/Em-v-abl mice developed tumors very rapidly and all were plasmacytomas (Rosenbaum et al., 1990) .
Our attempts to develop a transgenic model of CML had very limited success, probably due to the lack of an adequate vector. A bcr-v-abl gene that mimics the translocation junction, driven by a retroviral enhancer that functions well in myeloid cells but is also active in other cells, yielded T-cell lymphomas (Hariharan et al., 1989) and neuroectodermal tumors (unpublished results). Greater success has been obtained recently by others with a dierent transgenic vector (Honda et al., 1998) or by retroviral gene delivery (Elefanty et al., 1990; Daley and Ben-Neriah, 1991; Pear et al., 1998; Zhang and Ren, 1998) .
N-ras
The three ras genes (H, N and K) encode G proteins that serve in signal transduction pathways coupled in various cells to phenomena as diverse as proliferation, growth arrest, cell survival or apoptosis. In certain forms of leukemia, particularly acute myeloid leukemia, a substantial proportion of cases exhibit mutation of the N-ras gene (Bos, 1989; Rodenhuis, 1992) . Evidence that such mutations can initiate hematopoietic tumors has been provided by Em-N-ras mice. Curiously, two independent transgenic lines yielded both thymic T lymphomas and histiocytic sarcomas, apparently of macrophage origin (Harris et al., 1988b and unpublished results) . Somewhat paradoxically, no B lineage lymphomas have developed spontaneously in Em-N-ras mice, but the bi-transgenic progeny of their crosses with Em-myc mice rapidly developed pro-B and pre-B lymphomas (Harris et al., 1988b) . This result may indicate that ras and perhaps certain other oncogenes eectively initiate oncogenesis only in particular cell lineages but can contribute to tumor progression in others. However, a caveat about these results is that the N-ras transgene may be expressed at a low level or in only a minority of cells (our unpublished results).
Bcl-2
As reviewed in (Cory, 1995) , the bcl-2 gene is translocated to an immunoglobulin locus in most follicular center B-cell lymphomas and some chronic lymphocytic leukemias. Insight into its biological function arose when introduction of the gene into cytokine-dependent hematopoietic cell lines was shown to allow their survival but not proliferation in the absence of the growth factor (Vaux et al., 1988) . This seminal discovery established that cell survival is regulated separately from proliferation and that the function of Bcl-2 is to inhibit apoptosis. Thus, bcl-2 became the prototype of a new class of oncogene that extends cell survival rather than driving cell division. Indeed, this ®nding engendered the idea, gaining increasing acceptance, that perturbation of apoptosis may be a critical general step on the road to tumorigenesis.
Understanding of the biological eects of Bcl-2 have been considerably extended by the transgenic studies from Korsmeyer's group and our own (Cory et al., 1994a,b; Cory, 1995; Strasser, 1995b Strasser, , 1999b Strasser et al., , 1997a Chao and Korsmeyer, 1998; Cory et al., 1999) . Over-expression of Bcl-2 in the B-lymphoid lineage led to a several-fold expansion in the numbers of B cells and progressive increases in plasma cells that could culminate in autoimmune disease (McDonnell et al., 1989; Strasser et al., 1991b) . Because almost all the cells resided in the G0 phase of the cell cycle, this expansion cannot re¯ect increased proliferation but must instead re¯ect protection from a normal physiological program of cell death. Although Bcl-2 over-expression in the T lineage did not lead to a marked increase in cell numbers (Sentman et al., 1991; Strasser et al., 1991a Strasser et al., , 1994 ) (see, however, below), the T cells were protected from a great range of cytotoxic insults: corticosteroids, g-irradiation, drugs that induce DNA damage, calcium ionophores and phorbol esters, as well as factor deprivation. Thus, in ways that are still incompletely understood, Bcl-2 (and its subsequently discovered relatives) monitor many dierent types of cytotoxic signals and gauge whether the cell should live or die (Adams and Cory, 1998) .
Although the bcl-2 transgenes proved oncogenic, they were much less so than myc, with only some 5 ± 15% of mice succumbing in the ®rst year of life (McDonnell and Korsmeyer, 1991; Strasser et al., 1993) . It therefore seems unlikely that the human t(14;18) chromosomal translocation is sucient to generate follicular lymphoma. The tumors that arose in the transgenic mice were pre-B lymphomas or plasmacytomas/large cell lymphomas (McDonnell and Korsmeyer, 1991; Strasser et al., 1993) . Signi®cantly, the majority of the plasmacytomas contained a rearranged myc allele, implicating myc as a major oncogenic partner of bcl-2. Their cooperation in tumorigenesis was con®rmed by showing that the bitransgenic progeny of crosses rapidly developed tumors (Strasser et al., 1990a) . Surprisingly, although the very young animals showed a massive polyclonal expansion of pre-B cells, these cells were not malignant. Instead the tumors all proved to derive from a very early hematopoietic cell type, a progenitor cell capable of myeloid as well as B-lymphoid dierentiation (Strasser et al., 1996a) . Why this primitive cell type is so vulnerable remains a mystery.
In addition to its well-established role in control of cell survival, Bcl-2 can, under certain conditions, accelerate exit from the cell cycle and retard re-entry (Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996; Vairo et al., 1996) . These functions appear to be distinct, because mutation of a residue near the Nterminus of Bcl-2 (tyrosine 28) ablates the cell cycle eects while leaving the anti-apoptotic function intact (Huang et al., 1997) . Most likely, a protein that binds to this region of Bcl-2 initiates the cell cycle inhibition. Although the pathway is unknown, two members of the pRB family, p107 and p130, appear to be required to promote the quiescent state (G Vairo and J Adams, unpublished results). An intriguing possibility is that this function of Bcl-2 accounts for its association with very indolent tumors. If so, disruption of that function may be a step in the progression of those tumors. Intriguingly, in many human follicular lymphomas that have progressed to a more aggressive form, the translocated bcl-2 coding region has undergone mutation in the general vicinity of tyrosine 28 (Tanaka et al., 1992; Matolcsy et al., 1996) .
It seems clear from these results that Myc and Bcl-2 aect cells in very dierent ways: Myc drives unwarranted proliferation with an associated high level of apoptosis, whereas Bcl-2 promotes unwarranted survival in the quiescent state. The ability of Bcl-2 to counter Myc-induced apoptosis may account for much of their synergy. Conversely, Myc presumably can override the cell cycle inhibitory eect of Bcl-2.
Signaling by`death receptors' in lymphomagenesis
Not all pathways to apoptosis are controlled by the Bcl-2 protein family (Strasser, 1995a,b) . Studies with lymphocytes from bcl-2 transgenic mice have shown that Bcl-2 cannot block apoptosis triggered by ligation of the CD95 (Fas/APO-1)`death receptor' (Strasser et al., 1995) . Indeed, a bcl-2 transgene expressed in B and T cells accelerated and enhanced lymphadenopathy in lpr mice, which lack CD95 (Strasser et al., 1995) . Moreover, one expressed in the myeloid cells of lpr mice elicited acute myeloblastic leukemia (Traver et al., 1998) . These studies re-enforce the notion that the pathways to death triggered by`death receptors' are very largely distinct from those regulated by Bcl-2. Consistent with this model, transgenic expression of cowpox virus CrmA, which inhibits caspase-8, completely blocked CD95-transduced apoptosis but had no eect on those inhibitable by Bcl-2 (Smith et al., 1996) . A similar conclusion emerged from analysis of T cells expressing a dominant-interfering mutant of FADD (Newton et al., 1998) , an adaptor that recruits and processes caspase-8 upon death receptor ligation (Boldin et al., 1995; Chinnaiyan et al., 1995) . Studies with mice lacking caspase-8 (Varfolomeev et al., 1998) or FADD (Yeh et al., 1998; have con®rmed that both are required for`death receptor' signaling but not for other cell death pathways, whereas the opposite held for mice lacking caspase-9 Kuida et al., 1998) or its adaptor Apaf-1 (Cecconi et al., 1998; Yoshida et al., 1998) . It therefore appears that the Bcl-2 family regulates the response to the cytotoxic signals provoked by DNA damage, corticosteroids and probably some physiologically activated pathways to apoptosis, which all require Apaf-1-mediated processing of caspase-9, but Bcl-2 has little eect on the pathway induced by`death receptors'.
Abnormalities in`death receptor' signaling can contribute to tumorigenesis. Older lpr mice, particularly those lacking T cells, develop plasmacytoma (Peng et al., 1996; Davidson et al., 1998) . Moreover, the lpr mutation accelerates lymphoma onset in Em-Lmyc transgenic mice (ZoÈ rnig et al., 1995) and, as mentioned above, cooperates with bcl-2 in leukemogenesis (Traver et al., 1998) . So far no tumors have developed in mice that express a FADD-DN transgene (our unpublished observations), perhaps because FADD is needed not only for`death receptor'-activated apoptosis but also, unexpectedly, for mitogen-induced proliferation of T cells (Newton et al., 1998; .
Cyclin D1
The three D cyclins, which are synthesized in response to mitogenic stimulation of the cell, function (largely redundantly) to regulate progression through the G1 phase of the cell cycle (Sherr, 1996) . Each serves as an essential positive regulatory subunit for the cyclindependent kinases Cdk-4 and Cdk-6, whereas the negative regulators associating with these kinases include the tumor suppressor p16. The essential target of Cdk-4 and Cdk-6 is the retinoblastoma tumor suppressor protein pRB, which guards a critical checkpoint to G1/S progression and is inactivated by hyperphosphorylation (Vooijs and Berns, 1999) . Elimination of that normal checkpoint is now thought to be a general step in tumorigenesis, because the vast majority of tumors contain mutations that either remove pRB itself or promote its inactivation by augmenting Cdk-4 activity, usually by inducing cyclin D expression or eliminating p16 (Sherr, 1996) .
Because the cyclin D1 gene is translocated to the Igh locus in the vast majority of mantle-zone B lymphomas (Motokura and Arnold, 1993), Em-cyclin D1 mice were produced to test its lymphomagenic impact (Bodrug et al., 1994; Lovec et al., 1994) . Disappointingly, their spontaneous tumor incidence was near background. The transgene did, however, exhibit clear cooperativity with myc transgenes and also slightly enhanced rasinduced lymphomagenesis (Bodrug et al., 1994) . These results may mean that cyclin D1 falls into a class of oncogene that contributes to tumor progression but is poor at initiating the process. Another example of such an oncogene may be the recently discovered Frat1 gene (Jonkers et al., 1997) .
Interestingly, the endogenous cyclin D1 gene, which is not normally expressed in lymphocytes, was turned on in many spontaneous Em-myc lymphomas, and it was also found to be induced by Ras (Bodrug et al., 1994) . Hence cyclin D1 may be one of the genes needed to boost the cell cycle eects of Myc, presumably because they act at complementary steps. For example, Myc might directly or indirectly enhance cyclin E/Cdk-2 activity (Amati et al., 1998 ) (see below).
Despite the seemingly high level of cyclin D1 present in both B and T cells from the Em-cyclin D1 animals, no alteration in cell cycle kinetics or mitogen responsiveness was discernable, either in vivo or in subsequent cell culture studies (Bodrug et al., 1994; Warner, 1998) . This result was not altogether unexpected, because G1 to S progression requires not only cyclin D/Cdk-4 but also cyclin E/Cdk-2, which has essential targets in addition to pRb (Sherr, 1996) . The lymphoid compartments of the mice appeared unaected, with the apparent exception that very young animals contained fewer mature B and T cells (Bodrug et al., 1994) . This observation may point towards a role for cyclin D1 in the control of dierentiation, but its signi®cance is uncertain, because no similar eects appeared in adults and subsequent extensive cell culture studies have revealed no alteration in lymphocyte dierentiation (Warner, 1998) .
Insertional mutagenesis and oncogene synergy
Insertional mutagenesis with retroviruses (`proviral tagging') provides a powerful means for identifying oncogenes that can collaborate with the transgenic oncogene (reviewed by Jonkers and Berns, 1996) . The principle is that retroviruses that lack an oncogene, such as Moloney murine leukemia virus, promote tumors primarily by inadvertent insertion near or within a cellular oncogene, thereby enforcing their expression or altering their structure. Hence, the inserted provirus tags the relevant gene, as ®rst shown by the activation of myc genes in Em-pim-1 mice (van Lohuizen et al., 1989) . With Em-myc mice, this approach yielded not only the known pim-1 and pim-2 genes, which encode serine/threonine protein kinases, but also a previously unknown gene encoding a zinc ®nger protein denoted bmi-1 van Lohuizen et al., 1991b) . The synergy between myc and pim-1 in bi-transgenic animals was extremely high (Verbeek et al., 1991) . Similarly, generation of Em-bmi-1 mice con®rmed that this gene could trigger lymphomagenesis and collaborate with myc in their development (Haupt et al., 1993a; Alkema et al., 1997) .
Clues to the oncogenic role of Bmi-1 have been provided by van Lohuizen, Berns and their colleagues. Over-expression of Bmi-1, which has features of a chromatin modeling protein of the Polycomb group (van Lohuizen et al., 1991a) , causes homeotic transformations, suggesting that Bmi-1 may repress expression of certain homeobox genes (Alkema et al., 1995) . Probably more relevant for oncogenesis, Bmi-1 promotes immortalization of ®broblasts, apparently because it can down-regulate expression of the p16 locus, including that of its p19 alternative reading frame (ARF), which is normally induced by p53 (Jacobs et al., 1999) . By subverting not only the critical p16-pRB checkpoint but also that controlled by p53-p19 (Roussel, 1999) , elevated Bmi-1 may contribute greatly to escape from cellular senescence as well as sustain cell cycling.
In Em-N-ras mice insertional mutagenesis led to accelerated development of T lymphomas bearing proviruses near the myc or N-myc gene, con®rming the Myc-Ras synergy in tumorigenesis (Haupt et al., 1992) . Similarly, in Em-v-abl mice, the myc, N-myc and pim-1 genes were tagged as oncogenic partners (Haupt et al., 1993b) .
As discussed further elsewhere (Adams and Cory, 1992; Metz et al., 1995) , the development of hematopoietic malignancy is often associated with enhanced proliferative capacity, reduced growth factor dependence, impaired dierentiation, progression towards an inde®nite lifespan (immortalization) and reduced apoptosis. Constitutive Myc expression appears to contribute to the ®rst four of these changes, although it is clearly not sucient for either autonomous growth or immortalization and it only retards dierentiation.
Among the genes that collaborate with Myc, Bcl-2 seems to have the best de®ned role, but how the others contribute remains somewhat speculative and may depend greatly on cellular context. The v-abl gene, for example, may contribute to growth factor independence (Hariharan et al., 1988) and, at least in pre-B cells, appears also to block dierentiation. The ras genes contribute to cell cycle progression, for example by induction of cyclin D expression, but even the potent Myc plus Ras (or Raf) combination is not sucient for autonomous growth in all cells, and Ras can have other eects. As indicated above, Bmi-1 may have a role in breaking the Hay¯ick limit as well as driving proliferation. Mutation or deletion of the tumor suppressor p53 probably has multiple eects (Jacks, 1999). Its loss contributes strongly to immortalization of hematopoietic cells, e.g. (Metz et al., 1995) . In addition, the wild-type p53 protein is important for eliminating cells that have suered DNA damage, either by promoting growth arrest (via the p21 cell cycle inhibitor) or by promoting apoptosis, via poorly understood mechanisms that, in some cell types, seem to involve the bax gene (Gottlieb and Oren, 1998) . Thus, there are numerous pathways to lymphoid neoplasia, and not all involve mutation of the myc gene.
Eects of genetic background
It seems very unlikely that humans carry many alleles that either enhance or reduce the likelihood that an individual will develop speci®c types of tumors. That has proven to be the case for the various inbred strains of mice. For instance, shifting an Em-myc transgene on to dierent genetic backgrounds has revealed that lymphoma onset is much earlier on an SJL or BALB/c than a C57BL/6 background (Harris, 1991; Cory et al., 1999) . Similarly, with plasmacytoma induction by an Em-v-abl transgene, the incidence in BALB/c mice was 80% within 7 months, but less than 20% at 12 months on a C57BL/6 background (Harris et al., 1997) . With the growing number of genetic markers in the mouse, it should be feasible to map and eventually identify some of the genes relevant to such transgenic models. An ongoing study of plasmacytoma susceptibility by A Harris with Drs A Symons and S Foote has provided suggestive linkage to three loci (Symons et al., unpublished results) . Identi®cation of such modulating genes could provide a new window on the tumorigenic process.
A transgenic vector for the entire hematopoietic compartment
Vav regulatory elements
The vav gene is expressed in virtually all hematopoietic cell lines and, commencing in the fetal liver, in all normal hematopoietic cell types but in very few others (Katzav et al., 1989; Coppola et al., 1991; Bustelo et al., 1993) . To clarify its transcriptional regulation, we ®rst sought sites where the chromatin surrounding the gene had been rendered hypersensitive to DNaseI and delineated ®ve such sites within a 14-kb region spanning its ®rst exon (Ogilvy et al., 1998) . Because all ®ve sites appeared in dierent hematopoietic cell types and not in non-hematopoietic cells, they constituted prime candidates for the key vav regulatory elements. To test their activity, we ®rst coupled various combinations of the sites to the widely used E. coli lacZ (bgalactosidase) gene as a reporter. Transgenes that included four or ®ve of these sites did yield bgalactosidase-expressing cells in hematopoietic but not other tissues. Disappointingly, however, the expression was invariably con®ned to lymphocytes and was always variegated, i.e. restricted to a proportion of the cells of a given type (Ogilvy et al., 1998) . Moreover, that proportion gradually dropped, in a fashion consistent with stochastic inactivation.
Variegation of expression induced by the reporter
As reviewed recently (Martin and Whitelaw, 1996; Kioussis and Festenstein, 1997) , variegated expression, ®rst observed in Drosophila and yeast, has now been recognized in mice with a number of transgenes. A plausible interpretation for the variegation is that the activity of the transgene, like that of other transcription units, is primarily determined for each cell in a binary,`all-or-none' fashion (Walters et al., 1996) . In a given cell the probability of its activity is set by competition between positive in¯uences from its promoter and enhancer or locus control region, and negative in¯uences from surrounding chromatin (Martin and Whitelaw, 1996; Kioussis and Festenstein, 1997; Higgs, 1998) , and perhaps also from any foreign elements within the transgene itself.
Although the limitations in vav-lacZ expression might have re¯ected the need for unidenti®ed additional vav regulatory elements, it seemed possible that vav regulation had instead been compromised by the bacterial reporter itself. We therefore tested the eect of replacing lacZ with a mammalian reporter, a biologically inert form of the human CD4 cell surface antigen. Remarkably, the vav-CD4 transgenes were active in *80% of primary transgenic mice and were expressed eciently throughout the hematopoietic compartment but not detectably in non-hematopoietic tissues (Ogilvy et al., 1999) . None of the independent progeny lines tested exhibited variegation, and expression was entirely stable for at least 12 months. Figure 1 contrasts a typical vav-acZ result ( Figure  1a ) with that usually obtained with vav-CD4 ( Figure  1b ). It appears that the prokaryotic reporter both prevented expression in several hematopoietic lineages and, in lymphocytes, induced sporadic irreversible silencing of the transgene. This conclusion may seem surprising, because lacZ has been widely used, particularly in studies on embryogenesis. However, a review on lacZ as a transgenic reporter (Cui et al., 1994) concluded that`its postnatal in vivo expression has been unreliable and disappointing'. Its erratic performance in long-term experiments would be explicable if the bacterial sequences stochastically inactivated certain linked promoters, so that the proportion of non-expressing cells increased over time.
In striking contrast to the lacZ mice, adult vav-CD4 animals exhibited transgene activity in every nucleated hematopoietic cell type examined, including B and T lymphocytes, neutrophils, monocytes, megakaryocytes, eosinophils and nucleated erythroid cells (Ogilvy et al., 1999) . The highest level appeared in lymphocytes, eosinophils and megakaryocytes, while monocytes and neutrophils had an intermediate level, and erythroid cells the lowest. Signi®cantly, all clonogenic progenitors assayed also bore hCD4, including not only those committed to the neutrophil, monocyte/macrophage, eosinophil and megakaryocyte lineages, but also the more ancestral uncommitted progenitors, which yield blast cell progeny. In the embryo, hCD4 appeared on de®nitive erythroid cells and, at higher levels, on minor non-erythroid populations but was not detectable on the primitive erythroid cells, which derive from the yolk sac. Thus, with this sole exception, the vav transgene appears to be active throughout the hematopoietic system, both in the cells near its apex as well as in all the mature progeny.
Vav-bcl-2 transgene
The success with vav-CD4 encouraged us to explore further the impact of Bcl-2 on hematopoiesis by generating and characterizing vav-bcl-2 transgenic mice (Ogilvy et al., manuscript in preparation) . Again, the vav promoter region very eectively targeted expression of hBcl-2 throughout the hematopoietic compartment. Indeed, essentially all nucleated cells in hematopoietic tissues expressed abundant Bcl-2, and the levels in their lymphocytes indicate that the vav promoter probably is more potent than our well-tested Em transgenic vectors. Moreover, enhanced clonogenic survival con®rmed that the transgene was also very active in all tested progenitor cell types. In contrast, immunoblots with various non-hematopoietic tissues revealed either no hBcl-2, or levels attributable to resident Vavexpressing hematopoietic cells. Figure 1 Comparison of expression of a vav-driven lacZ (bgalactosidase) transgene (a) and a vav-hCD4 transgene (b) in the peripheral blood of progeny mice. All vav-lacZ transgenic lines exhibited variegated expression, with b-galactosidase detectable in only a minority of blood cells, whereas all vav-hCD4 progeny animals showed expression in essentially all these cells Constitutive Bcl-2 expression provoked a marked rise not only in lymphocytes but also in non-lymphoid cells such as neutrophils and macrophages. In the Bcell lineage, mature B cells rose tenfold, somewhat higher than with Em-driven bcl-2 transgenes (McDonnell et al., 1989; Strasser et al., 1991b) . Similarly, the eects on T lymphopoiesis were more marked than those previously reported (Sentman et al., 1991; Strasser et al., 1991a) . T-cell development in the thymus was clearly disturbed, and in the periphery both the helper (CD4 + ) and the cytotoxic (CD8 + ) populations were elevated. Thus, the vav vector reveals Bcl-2 eects in multiple lineages.
Potential of multilineage hematopoietic targeting
Our results with both CD4 (Ogilvy et al., 1999) and with Bcl-2 (Ogilvy et al., in preparation) demonstrate that the vav regulatory elements we have identi®ed can confer pan-hematopoietic expression upon a linked gene in most chromosomal positions. Because all ®ve vav hypersensitive sites appear in several hematopoietic lineages and not in ®broblasts (Ogilvy et al., 1998) , these sites may normally act together in a fashion akin to a locus control region, both to open the surrounding chromatin within hematopoietic stem cells and to maintain this open state during subsequent differentiation.
Because the other available transgenic promoters for hematopoietic cells function in only one or two lineages, or at particular dierentiation stages, the ability of the vav promoter to target expression throughout the compartment should facilitate studies on many aspects of hematopoiesis. For instance, vavdriven expression of transcription factors implicated in lineage commitment should clarify whether they actually impose lineage speci®cation. Similarly, because certain leukemias are thought to arise in stem cells, a vav transgenic vector should facilitate tests on putative oncogenes. Conversely, a vav-driven Cre recombinase might allow hematopoietic-speci®c knockout' of genes with wider essential function.
